Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

CD34+/TNC ratio predicts relapse in AML/MDS patients receiving peripheral blood matched allogeneic stem cell transplantation with post-transplant cyclophosphamide

View Full Paper
Ask AI
Bookmark
Share

Authors

RSRima M. SalibaIKIndreshpal KaurPKPartow Kebriaei

Discussion

Loading...

Member takes

Overview

Analysis shows CD34+/TNC ratio predicts relapse and progression-free survival in AML/MDS patients undergoing allogeneic stem cell transplantation.

Key Points

  • Evaluate the impact of graft composition on outcomes after allogeneic stem cell transplantation in patients with AML/MDS.
  • Assessed patients receiving matched unrelated or related stem cell transplantation with cryopreserved peripheral blood cells and post-transplant cyclophosphamide.
  • Analyzed CD34+ cells, TNC, and the CD34+/TNC ratio for post-transplant outcomes using quartile analyses.
  • Conducted multivariate analysis to evaluate predictors of progression-free survival and relapse rates.
  • Lower CD34+/TNC ratio correlated with poorer outcomes in AML/MDS patients receiving allogeneic stem cell transplantation.
  • High-risk of relapse and lower progression-free survival identified in patients with low CD34+/TNC ratio.
  • G4 group associated with higher chronic graft-versus-host disease rates compared to lower ratio groups.

Cite This Study

Saliba et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236dba0https://doi.org/10.1182/blood-2025-5994
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Post-transplant monitoring of multiparameter flow-cytometry (MFC)-based measurable residual disease (MRD) assessment combined with T-cell chimerism following allogeneic stem cell transplantation (HCT) in Acute Myeloid Leukemia (AML) and myelodysplastic syndrome (MDS)2025
  2. 2CD34 <sup>+</sup> cell dose - Predictors and effect on patient outcome in hematopoietic stem cell transplant2026 · 1 citations
  3. 3Post-transplant cyclophosphamide (PTCy) versus other graft-versus-host disease prophylaxis strategies in reduced intensity allogeneic stem cell transplantation from related and matched unrelated donors in patients with acute myeloid leukemia and myelodysplastic syndromes: A study from the french society of bone marrow transplantation (SFGM-TC) registry2025
  4. 4Reduced dose post-transplant cytoxan (Intermediate -Dose) in combination with abatacept after matched unrelated donor transplant for high -risk hematological malignancy may reduce treatment related mortality and risk of relapse.2025
  5. 5Outcomes after bone marrow versus peripheral blood mismatched unrelated donor hematopoietic cell transplantation using posttransplant cyclophosphamide-based GVHD prophylaxis2025